Free Trial

Instil Bio (TIL) Competitors

Instil Bio logo
$28.78
-2.99 (-9.41%)
(As of 11/1/2024 ET)

TIL vs. RLAY, ETNB, IMTX, ERAS, ABUS, IMNM, REPL, CRMD, PHVS, and ANNX

Should you be buying Instil Bio stock or one of its competitors? The main competitors of Instil Bio include Relay Therapeutics (RLAY), 89bio (ETNB), Immatics (IMTX), Erasca (ERAS), Arbutus Biopharma (ABUS), Immunome (IMNM), Replimune Group (REPL), CorMedix (CRMD), Pharvaris (PHVS), and Annexon (ANNX). These companies are all part of the "pharmaceutical products" industry.

Instil Bio vs.

Instil Bio (NASDAQ:TIL) and Relay Therapeutics (NASDAQ:RLAY) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, community ranking, analyst recommendations and profitability.

60.6% of Instil Bio shares are owned by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are owned by institutional investors. 46.5% of Instil Bio shares are owned by company insiders. Comparatively, 4.3% of Relay Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Instil Bio currently has a consensus target price of $110.00, indicating a potential upside of 282.21%. Relay Therapeutics has a consensus target price of $21.11, indicating a potential upside of 261.49%. Given Instil Bio's higher probable upside, analysts plainly believe Instil Bio is more favorable than Relay Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Instil Bio
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
Relay Therapeutics
0 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.90

Instil Bio has higher earnings, but lower revenue than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Instil BioN/AN/A-$156.09M-$18.42-1.56
Relay Therapeutics$25.55M30.60-$341.97M-$2.52-2.32

In the previous week, Relay Therapeutics had 8 more articles in the media than Instil Bio. MarketBeat recorded 9 mentions for Relay Therapeutics and 1 mentions for Instil Bio. Instil Bio's average media sentiment score of 0.76 beat Relay Therapeutics' score of -0.01 indicating that Instil Bio is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Instil Bio
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Relay Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Instil Bio received 44 more outperform votes than Relay Therapeutics when rated by MarketBeat users. However, 67.50% of users gave Relay Therapeutics an outperform vote while only 50.52% of users gave Instil Bio an outperform vote.

CompanyUnderperformOutperform
Instil BioOutperform Votes
98
50.52%
Underperform Votes
96
49.48%
Relay TherapeuticsOutperform Votes
54
67.50%
Underperform Votes
26
32.50%

Relay Therapeutics' return on equity of -43.66% beat Instil Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Instil BioN/A -55.57% -37.76%
Relay Therapeutics N/A -43.66%-38.38%

Instil Bio has a beta of 1.73, meaning that its share price is 73% more volatile than the S&P 500. Comparatively, Relay Therapeutics has a beta of 1.67, meaning that its share price is 67% more volatile than the S&P 500.

Summary

Instil Bio and Relay Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TIL vs. The Competition

MetricInstil BioBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$187.07M$3.14B$5.39B$8.53B
Dividend YieldN/A1.77%5.13%4.14%
P/E Ratio-1.5612.18113.8115.12
Price / SalesN/A332.371,483.2593.03
Price / CashN/A148.6339.6434.05
Price / Book0.834.024.665.02
Net Income-$156.09M-$42.25M$119.06M$225.46M
7 Day Performance-7.34%8.08%0.79%0.37%
1 Month Performance-50.38%8.72%5.65%3.57%
1 Year Performance273.77%32.11%36.76%29.42%

Instil Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TIL
Instil Bio
3.1455 of 5 stars
$28.78
-9.4%
$110.00
+282.2%
+293.2%$187.07MN/A-1.5649Gap Down
RLAY
Relay Therapeutics
3.2138 of 5 stars
$6.02
-2.7%
$21.11
+250.7%
-14.5%$799.11M$35.21M-2.39304Upcoming Earnings
News Coverage
ETNB
89bio
1.7435 of 5 stars
$7.87
+1.3%
$31.00
+293.9%
+15.5%$798.88MN/A-3.9940News Coverage
IMTX
Immatics
1.5725 of 5 stars
$9.26
-2.8%
$17.50
+89.0%
+19.6%$783.93M$70.87M-10.40260Short Interest ↑
ERAS
Erasca
2.6092 of 5 stars
$2.64
+2.3%
$6.10
+131.1%
+19.8%$754.29MN/A-2.87126Gap Up
ABUS
Arbutus Biopharma
2.2958 of 5 stars
$3.97
-2.0%
$5.25
+32.2%
+115.2%$749.21M$10.06M-8.8273Upcoming Earnings
IMNM
Immunome
2.4993 of 5 stars
$12.11
+0.8%
$29.00
+139.5%
+35.2%$727.21M$14.02M-1.5740Short Interest ↓
Gap Up
REPL
Replimune Group
3.6999 of 5 stars
$11.73
-1.9%
$16.80
+43.2%
-16.7%$720.40MN/A-3.59210Upcoming Earnings
CRMD
CorMedix
2.6988 of 5 stars
$13.04
+4.6%
$13.60
+4.3%
+193.8%$716.67M$806,119.00-14.0230Earnings Report
Analyst Forecast
News Coverage
High Trading Volume
PHVS
Pharvaris
2.058 of 5 stars
$21.71
+1.8%
$33.60
+54.8%
+42.8%$691.25MN/A-8.4130Upcoming Earnings
ANNX
Annexon
1.4361 of 5 stars
$7.40
-0.5%
$15.80
+113.5%
+203.3%$683.86MN/A-6.0260

Related Companies and Tools


This page (NASDAQ:TIL) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners